First Australian Patient Dosed in ZIRCON Phase III Trial
MELBOURNE (Australia) – 20th August 2019. Telix Pharmaceuticals Limited has today announced that the first Australian patient has been added to the Phase III ZIRCON study.
Telix Pharmaceuticals Limited is pleased to announce that the first Australian patient has been added to the Phase III ZIRCON study. The first Australian patient was dosed with TLX250-CDx at Olivia Newton-John Cancer and Wellness Centre (Austin Health) on 20th August 2019, as part of the international ZIRCON (Zirconium Imaging in Renal Cancer Oncology) study.
To read the full report please click here.